For decades, the epilepsy community has addressed the burden ofdrug-resistant epilepsy by focusing on the development of new antiep-ileptic drugs (AEDs) and advancing epilepsy surgery techniques. Theseapproaches have resulted in some success, but the percentage of pa-tients with drug-resistant epilepsy has not changed substantially.More than 30% of individuals with epilepsy have persistent seizuresdespite the use of appropriate therapies, i.e., they have drug-resistantepilepsy [1–3]